Hubei Cancer Hospital ( Site 0107)

Wuhan, Hubei 430079

0 studies enrolling now · 1 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung

Studies at this site

• Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) — Running, not enrolling